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1WHY IS WHO UPDATING ITS 
HEPATITIS C TREATMENT GUIDELINES?
Globally, the morbidity and mortality attributable to hepatitis C virus (HCV) infection continues to 
increase. Approximately 700 000 persons die each year from HCV-related complications, which include 
cirrhosis and hepatocellular carcinoma (HCC). HCV infection can be cured by antiviral treatment; 
however, due to the asymptomatic nature of the disease, most infected persons are unaware of their 
infection and, for those who are diagnosed, access to treatment remains low in many settings.
The World Health Organization (WHO) issued the first Guidelines for the screening, care and 
treatment of persons with hepatitis C infection in 2014. Since then, several new medicines for 
the treatment of HCV infection have been introduced. Of these, daclatasvir, ledipasvir, and a 
combination of ombitasvir, paritaprevir and dasabuvir were added to the WHO Model List of 
Essential Medicines in 2015. These medicines are transforming the treatment of HCV, enabling 
the use of regimens that can be administered orally, are shorter in duration (as short as eight 
weeks), result in cure rates higher than 90%, and are associated with fewer serious adverse 
events (SAEs) than the previous interferon-containing regimens. 
The objectives of these updated WHO Guidelines are to provide evidence-based recommendations 
for the treatment of persons with hepatitis C infection using, where possible, all-oral combinations 
of these new medicines, also called direct-acting antivirals (DAAs). The Guidelines also provide 
recommendations on the preferred regimens based on a patient’s HCV genotype and clinical 
history, and assess the appropriateness of continued use of the existing medicines. The key 
audience for these guidelines are policy-makers in low- and middle-income countries who 
formulate country-specific treatment guidelines, and who plan infectious disease treatment 
programmes and services, in addition to those people responsible for delivering treatment. The 
Guidelines are appropriate for all countries, including high-income countries.
21. WHAT ARE THE NEW RECOMMENDATIONS 
IN THE UPDATED GUIDELINES?
1.1  Treatment with direct-acting antiviral agents
Treatment with DAA-based regimens have a short duration, are easy to administer (given orally), 
have a lower pill burden (as few as one pill/day), are very effective (sustained virological response 
[SVR] rates of ≥90%) and well tolerated, with few adverse events. Thus, they have the potential 
to be the basis for a large expansion in the number of persons treated. However, not all persons 
with HCV infection can be treated with DAAs alone, as pegylated interferon and/or ribavirin are 
needed for some genotypes.
1.2  Removal of recommendation for treatment with telaprevir or boceprevir
Telaprevir and boceprevir are first-generation protease inhibitors, which when administered with 
pegylated interferon/ribavirin to persons infected with HCV genotype 1, result in higher SVR rates 
as compared with pegylated interferon and ribavirin alone. As a result, they were included in the 
WHO 2014 Guidelines for the screening, care and treatment of persons with hepatitis C infection 
for consideration of treatment for genotype 1 HCV infection. However, these regimens result in 
high rates of SAEs. Compared with the newer DAAs, the treatment effectiveness of telaprevir- 
or boceprevir-containing regimens is lower and adverse effects are more frequent, and thus 
telaprevir- or boceprevir-containing regimens are no longer recommended by WHO.
It is recommended that direct-acting antiviral (DAA) regimens be used for the treatment of persons 
with hepatitis C infection rather than regimens with pegylated interferon/ribavirin.
Strong recommendation, moderate quality of evidence
Specific subgroup consideration
For patients with HCV genotype 3 infection with cirrhosis, and patients with genotypes 5 and 6 infection 
with and without cirrhosis, sofosbuvir/pegylated interferon and ribavirin is still recommended as an 
alternative treatment option.
Boceprevir- or telaprevir-containing regimens are no longer recommended for the treatment of persons 
with hepatitis C infection.
Strong recommendation, moderate quality of evidence
31.3  Preferred and alternative regimens for the treatment of persons with chronic 
hepatitis C virus infection
TABLE 1 Summary of recommended preferred regimens with treatment durations*
TABLE 2 Summary of recommended alternative regimens with treatment durations*
PATIENTS WITHOUT CIRRHOSIS
Daclatasvir / sofosbuvir Ledipasvir / sofosbuvir Sofosbuvir / ribavirin
Genotype 1 12 weeks 12 weeksa  
Genotype 2   12 weeks
Genotype 3 12 weeks  24 weeks
Genotype 4 12 weeks 12 weeks  
Genotype 5  12 weeks  
Genotype 6  12 weeks  
PATIENTS WITH CIRRHOSIS
Daclatasvir / 
sofosbuvir
Daclatasvir / 
sofosbuvir / 
ribavirin
Ledipasvir / 
sofosbuvir
Ledipasvir / 
sofosbuvir / 
ribavirin
Sofosbuvir / 
ribavirin
Genotype 1 24 weeks 12 weeks 24 weeks 12 weeksb  
Genotype 2     16 weeks
Genotype 3 24 weeks    
Genotype 4 24 weeks 12 weeks 24 weeks 12 weeksb  
Genotype 5   24 weeks 12 weeksb  
Genotype 6   24 weeks 12 weeksb  
PATIENTS WITHOUT CIRRHOSIS
Simeprevir /
sofosbuvir
Daclatasvir /
sofosbuvir
Ombitasvir / 
paritaprevir /
ritonavir / 
dasabuvir
Ombitasvir / 
paritaprevir / 
ritonavir / 
ribavirin
Sofosbuvir / 
pegylated 
interferon / 
ribavirin
Genotype 1 12 weeksa 12 weeksb
Genotype 2 12 weeks
Genotype 3
Genotype 4 12 weeks 12 weeks
Genotype 5 12 weeks
Genotype 6 12 weeks
* Treatment durations are adapted from 2015 AASLD and EASL guidelines.
a Treatment may be shortened to 8 weeks in treatment-naive persons without cirrhosis if their baseline HCV RNA level is below 6 million (6.8 log) IU/mL. 
  The duration of treatment should be shortened with caution.
b If the platelet count is <75 x 103/μL, then 24 weeks’ treatment with ribavirin should be given.
4PATIENTS WITH CIRRHOSIS
Simeprevir / 
sofosbuvir
Simeprevir / 
sofosbuvir / ribavirin
Daclatasvir / 
sofosbuvir
Sofosbuvir / 
pegylated interferon 
/ ribavirin
Genotype 1 24 weeksa 12 weeksa
Genotype 2 12 weeks
Genotype 3 12 weeks
Genotype 4 24 weeks 12 weeks
Genotype 5 12 weeks
Genotype 6 12 weeks
* Treatment durations are adapted from 2015 AASLD and EASL guidelines.
a If genotype 1a-infected patient is positive for Q80K variant, should not choose simeprevir/sofosbuvir regimen
b For genotype 1a-infected patient, treat with ombitasvir/paritaprevir/ritonavir/dasabuvir and ribavirin; for genotype 1b-infected patient treat with ombitasvir/
paritaprevir/ritonavir/dasabuvir.
Genotypes 1 and 4 regimens: strong recommendation, moderate quality of evidence 
Genotypes 2 and 3 regimens: strong recommendation, low quality of evidence
Genotypes 5 and 6 regimens: conditional recommendation, very low quality of evidence
The updated guidelines provide recommendations on the preferred and alternative DAA regimens 
by HCV genotype and cirrhosis status. The selected preferred and alternative regimens provide 
clinicians with the choice of prescribing interferon-free regimens for everyone (except patients 
who have both cirrhosis and genotype 3 infection, and those infected with genotypes 5 and 6). 
This dramatically simplifies implementation by lessening the requirement for genotype testing 
and reducing the risk of treatment discontinuation due to adverse events. Unfortunately, it is 
not yet possible to recommend a single regimen that could be used for all patients with HCV 
infection regardless of HCV genotype or degree of cirrhosis and previous treatment experience. 
It is anticipated that improved, truly pangenotypic regimens will soon become available.
How were these regimens selected?
The recommendations were produced using the Grading of Recommendations Assessment, 
Development and Evaluation (GRADE) method. Systematic reviews and network meta-analyses 
were conducted using evidence from all available clinical trials to assess the comparative efficacy 
and safety of antivirals for the treatment of HCV infection. Pooled proportions for SVR, SAEs, and 
treatment discontinuation and mortality rates were calculated for each regimen by genotype, 
stage of disease (with cirrhosis or without cirrhosis) and previous treatment experience.
The acceptability of different regimens from a patient’s perspective was classified as “high”, 
“moderate” and “low” depending on the requirement of ribavirin or interferon, the number of 
doses/day and the frequency of drug–drug interactions. Preferred regimens were those that 
had high efficacy and safety, and had a dosage schedule that was highly acceptable. Safe and 
effective regimens with moderate or low acceptability were classified as “alternative regimens”. 
Based on this, decision-makers are then able to choose from these preferred options based on 
local price, availability and feasibility of use. 
5Implementation considerations
DAA-only therapy is easier to administer and requires less patient monitoring than interferon-
containing therapy; therefore, it could be administered in non-specialized clinical settings such 
as primary-care clinics by health cadres such as primary-care doctors. This would lead to the 
availability of treatment in a wider range of settings, including those with populations such as 
people who inject drugs (PWID) and migrants, who are at high risk of infection but who have 
difficulty in accessing treatment services. As the recommended regimens vary by genotype, 
genotyping is still required except perhaps in countries where a single genotype predominates. 
However, other health system requirements, such as the need for laboratory monitoring, will be 
reduced because the treatment duration is shorter and the need for laboratory monitoring is less 
intense than with interferon-containing regimens due to less frequent adverse reactions to the 
medicines.
Cost and budget impact of implementing treatment with new DAAs
Initial prices of DAAs were prohibitively high. However, the prices of DAAs are falling in a 
number of countries as a result of price negotiations with the manufacturers, and through the 
introduction and registration of generic medicines. As a result of these lower prices, budget 
impact analyses demonstrate that in some countries, expanding access to treatment using 
interferon-free regimens will be less costly and result in better rates of cure than if traditional 
pegylated interferon-based regimens are used. 
6•  Increased risk of death: 
- advanced fibrosis and cirrhosis 
- post-liver transplantation
• Risk of accelerated fibrosis: 
- coinfection with either HIV or hepatitis B virus (HBV) 
- metabolic syndrome
•  Extrahepatic manifestations and evidence of end-organ damage 
- debilitating fatigue 
- vasculitis and lymphoproliferative disorders
•  Significant psychosocial morbidity (due to stigma, discrimination, fear of transmission to others)
•  Maximizing reduction in incidence: 
- PWID 
- men who have sex with men (MSM)  
- prisoners 
- sex workers 
- women with childbearing potential 
- health-care workers
2. PRIORITIZATION
A key question in implementing these recommendations is who should receive treatment.  WHO is not making a 
recommendation regarding this, but  guidelines of other organizations (e.g. AASLD and EASL) now recommend 
that all persons with HCV infection should receive treatment. Despite this, the scaling up of treatment is likely 
to remain restricted in many countries because of the continued high prices of medicines and lack of health-
care infrastructure (e.g. lack of laboratory capacity or trained health-care workers). Policy-makers will be faced 
with the challenge of how to prioritize treatment given limited resources. Therefore, it is important to have a 
framework to help policy-makers decide who to prioritize for treatment. 
Two broad criteria can be used to prioritize treatment: (i) minimizing mortality and morbidity by prioritizing those 
people with advanced HCV-related liver disease or who have factors that make them more likely to progress to 
cirrhosis; and (ii) maximizing the prevention benefit by prioritizing people at highest risk of transmitting HCV 
infection, for example, PWID. These factors are summarized below to assist policy-makers in making decisions 
on how best to prioritize treatment allocation. 
Factors to be considered in prioritizing treatment
73. PLANS FOR UPDATING
The interim guidelines will be updated regularly as more medicines become available and 
new evidence is published. The updated Guidelines for the screening, care and treatment of 
persons with hepatitis C infection, which will include these new recommendations in addition to 
recommendations on screening and care, will be released in April 2016.
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